OTCMKTS:PXSLY Pharmaxis (PXSLY) Stock Price, News & Analysis $0.88 0.00 (0.00%) As of 06/8/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pharmaxis Stock (OTCMKTS:PXSLY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharmaxis alerts:Sign Up Key Stats Today's Range$0.88▼$0.8850-Day Range$0.88▼$0.8852-Week Range$0.62▼$1.47VolumeN/AAverage Volume1,000 shsMarket Capitalization$26.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Read More… Receive PXSLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address PXSLY Stock News HeadlinesPharmaxis Ltd Highlights Uncertainties in Syntara’s Future ProjectionsMay 6, 2025 | tipranks.comPharmaxis Ltd March Quarter Shareholder UpdateApril 30, 2025 | tipranks.comTrump Knows Exactly What He's DoingREVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.June 1, 2025 | Brownstone Research (Ad)Syntara’s SNT-6302 Shows Promising Results in Scar Treatment TrialFebruary 17, 2025 | tipranks.comPharmaxis Ltd General Meeting Addresses Key ResolutionsFebruary 16, 2025 | tipranks.comPharmaxis Ltd Reveals Interim Results at Hematology ForumFebruary 3, 2025 | tipranks.comSyntara Reports Promising Interim Results for Myelofibrosis TreatmentJanuary 28, 2025 | tipranks.comPharmaxis Ltd Announces New Equity Raising InitiativeDecember 11, 2024 | tipranks.comSee More Headlines PXSLY Stock Analysis - Frequently Asked Questions How have PXSLY shares performed this year? Pharmaxis' stock was trading at $0.88 at the beginning of 2025. Since then, PXSLY shares have increased by 0.0% and is now trading at $0.88. View the best growth stocks for 2025 here. How do I buy shares of Pharmaxis? Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:PXSLY CIK1301357 Webwww.pharmaxis.com.au Phone61-2-9454-7200FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.82 Current Ratio3.31 Quick Ratio2.92 Sales & Book Value Annual Sales$8.75 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book22.00Miscellaneous Outstanding Shares30,150,000Free FloatN/AMarket Cap$26.53 million OptionableNot Optionable Beta1.22 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:PXSLY) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresident Trump Just Warned About Economic Pain Ahead - Are You Prepared?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.